<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712723</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011XUS10T</org_study_id>
    <nct_id>NCT02712723</nct_id>
  </id_info>
  <brief_title>Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer</brief_title>
  <acronym>FELINE</acronym>
  <official_title>Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qamar Khan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ribociclib in combination with letrozole for 24
      weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative
      Endocrine Prognostic Index (PEPI) score of 0 at surgery compared to patients treated with
      letrozole alone therefore allowing more patients excellent outcomes without chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized (1:1:1) to either letrozole plus placebo vs. letrozole plus
      continuous dosing of ribociclib vs. letrozole plus intermittent dosing
      (3-weeks-on/1-week-off) of ribociclib.

      The difference in clinical, pathologic and radiologic response as well as Pre-operative
      Endocrine Prognostic Index (PEPI) scores across the three treatments arms will be examined.
      Subjects will also be followed for 5 years post-treatment to determine if ribociclib in
      combination with letrozole for 24 weeks results in improved 5 year Relapse Free Survival
      (RFS) compared to letrozole alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Pre-operative Endocrine Prognostic Index (PEPI) score 0 at surgery between ribociclib containing arms (combined) vs letrozole alone arm</measure>
    <time_frame>At Surgery (22 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete cell cycle arrest at 2 weeks between ribociclib containing arms (combined) vs letrozole alone arm: Complete cell cycle arrest is defined as Ki67 at day 14 of &lt; 2.7%</measure>
    <time_frame>Day 14 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate (pCR rate): pCR rate is defined as the proportion of patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary lymph nodes</measure>
    <time_frame>At Surgery (Days 8-15 of Cycle 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response rate (cCR rate): cCR rate is defined as the proportion of patients with no residual tumor by clinical exam</measure>
    <time_frame>Post-surgery (Once in the first 4 weeks of post-op, then once every 6 months for 5 years post-op)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Year Relapse Free Survival (RFS)</measure>
    <time_frame>5 years post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo + Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribociclib 600 mg + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribociclib 400 mg + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Nonsteroidal aromatase inhibitor</description>
    <arm_group_label>Placebo + Letrozole</arm_group_label>
    <arm_group_label>Ribociclib 600 mg + Letrozole</arm_group_label>
    <arm_group_label>Ribociclib 400 mg + Letrozole</arm_group_label>
    <other_name>Femara</other_name>
    <other_name>CGS 20267</other_name>
    <other_name>LTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Oral cyclin-dependent kinase (CDK) inhibitor</description>
    <arm_group_label>Ribociclib 600 mg + Letrozole</arm_group_label>
    <arm_group_label>Ribociclib 400 mg + Letrozole</arm_group_label>
    <other_name>LEE011</other_name>
    <other_name>LEE-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for ribociclib</description>
    <arm_group_label>Placebo + Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Pathologically confirmed invasive breast cancer by core needle biopsy

          -  Female subjects, age ≥ 18 years

          -  Only postmenopausal women will be eligible.

          -  Performance Status: Eastern Cooperative Oncology Group (ECOG) score 0-2

          -  Invasive breast cancer must be ER+ in ≥66 % of the cells or ER Allred score 6-8

          -  Invasive breast cancer must be HER2 negative.

          -  Clinical Stage II or III (by clinical measurement and/or breast imaging)

        Key Exclusion Criteria:

          -  Subjects meeting any of the exclusion criteria at baseline will be excluded from study
             participation.

          -  Current use of other investigational agents

          -  Inflammatory breast cancer defined as clinically significant erythema of the breast
             and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau
             d'orange without erythema)

          -  An excisional biopsy of this breast cancer

          -  Surgical axillary staging procedure prior to study entry

          -  Hormone replacement therapy of any type, megestrol acetate, or raloxifene within four
             weeks prior to first study treatment

          -  Clinical or radiographic evidence of metastatic disease

          -  Clinically significant, uncontrolled heart disease

          -  Herbal preparations/medications as listed in Appendix B of the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qamar Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Nurse Navigator</last_name>
    <phone>913-945-7552</phone>
    <email>ctnursenav@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Issam Makhoul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Yuan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Collaboration</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shlomit Ein-Gal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Jahanzeb, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - West</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Westwood</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditya Bardia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghna Trivedi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Wisinski, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Qamar Khan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ER+, HER2-negative breast cancer</keyword>
  <keyword>Stage II or III</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Femara</keyword>
  <keyword>Ribociclib</keyword>
  <keyword>LEE011</keyword>
  <keyword>Neo-adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

